

T cell control of HIV: A tale in six brief chapters

New England Cytometry Meeting
October 25, 2018

Chapter 1.

A New Disease

Learning from patients: 1981

- 19 year old male transferred to MGH
Previously well
 - Profound weight loss
 - TB in sputum, on Rx
 - Acute change in mental status
- Presumptive diagnosis on transfer:
 - Pulmonary TB with TB meningitis

Diagnoses


- Brain:
 - No TB
 - Mass lesion: lymphoma
- Lung:
 - No TB
 - Multiple mass lesions : Kaposi's sarcoma and pneumocystis pneumonia
- Abdomen:
 - No TB
 - Multiple masses: Kaposi's sarcoma
 - Disseminated CMV infection of the colon


Chip Schooley
and Marty Hirsch,
ca. 1984





HIV is an infection of the immune system





DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICEINDIVIDUAL NATIONAL RESEARCH SERVICE
AWARD APPLICATION

FOLLOW INSTRUCTIONS CAREFULLY

☐ PREDOCTORAL ☒ POSTDOCTORAL ☐ OTHER:

LEAVE BLANK

TYPE	ACTIVITY	NUMBER
REVIEW GROUP		FORMERLY
MEETING DATES		DATE RECEIVED

1. TITLE OF TRAINING PROPOSAL (Do not exceed 56 typewriter spaces)

CELL MEDIATED IMMUNE RESPONSE TO HTLV-III

2. PROGRAM ANNOUNCEMENT AREA

NATIONAL INSTITUTES OF HEALTH

3. APPLICANT

3a. NAME OF APPLICANT (Last, first, middle initial)

WALKER, BRUCE D.

3b. SOCIAL SECURITY NO.

3c. PRESENT MAILING ADDRESS (Street, city, state, zip code)

INFECTIOUS DISEASE UNIT
MASSACHUSETTS GENERAL HOSPITAL
FRUIT STREET
BOSTON, MA 02114

3d. PERMANENT MAILING ADDRESS (Street, city, state, zip code)

MASSACHUSETTS GENERAL HOSPITAL
INFECTIOUS DISEASE UNIT
FRUIT STREET
BOSTON, MA 021143e. OFFICE TELEPHONE NO.
(Area code, no., and ext.)

617-726-3812

3f. HOME TELEPHONE NO.
(Area code, no., and ext.)

3g. PERMANENT TELEPHONE NO. (Area code, no., and ext.)

617-726-3812

3h. ☒ U.S. CITIZEN OR U.S. NONCITIZEN NATIONAL OR ☐ PERMANENT RESIDENT OF U.S. (Notarized statement required)

PERSONAL SERVICE AWARD SUPPORT (Individual and/or Institutional)

HIV-specific CD8⁺ T cells

HIV-specific cytotoxic T lymphocytes in seropositive individuals

**Bruce D. Walker*, Sekhar Chakrabarti†,
Bernard Moss†, Timothy J. Paradis*, Theresa Flynn*,
Amy G. Durno*, Richard S. Blumberg*,
Joan C. Kaplan*, Martin S. Hirsch*
& Robert T. Schooley***

* Infectious Disease Unit, Massachusetts General Hospital and
Harvard Medical School, Boston, Massachusetts 02114, USA
† Laboratory of Viral Diseases, National Institute of Allergy and
Infectious Diseases, National Institutes of Health, Bethesda,
Maryland 20892, USA

AIDS virus-specific cytotoxic T lymphocytes in lung disorders

**Fernando Plata*, Brigitte Autran†,
Livia Pedroza Martins*, Simon Wain-Hobson*,
Martine Raphaël†, Charles Mayaud‡,
Michel Denis‡, Jean-Marc Guillon‡
& Patrice Debré†**

* Laboratoire de Biologie et d'Immunologie Moléculaires des
Rétrovirus, Institut Pasteur, 75724 Paris Cédex 15, France
† Laboratoire d'Immunologie Cellulaire et Tissulaire,
Hôpital Pitié-Salpêtrière, 75013 Paris, France
‡ Service de Pneumologie, Hôpital Tenon, 75010 Paris, France

Nature 328:345, 1987

Nature 328:348, 1987

Chapter 2.

Outliers

Mami.

1978 2wk pre Thanksgiving

→ Sx hard to describe

Sudden onset very severe flu

doing something at desk →

Sudden feeling of extreme fatigue
"frozen in mud"

Happened 2-3 times → over 1-2 d.

Called NY Hosp — ? cult leucocytes

To hosp. w/ aspirin

CT scan → R/O

Improving faster
Worsening.

long diagnostic process


7-10 d in hosp.

HA

? Temp.

? swollen glands

samples.




tion in Si(100) has intriguing consequences. Besides providing a logical pathway from adatom adsorption and diffusion to growth of islands, these chain structures and their prevalence suggest that the smallest and most obvious stable structure on the surface, the ad-dimer residing on top of the dimer rows, does not participate

metastable structures that may have a variety of sizes.

REFERENCES AND NOTES


1. For a review and an extended list of references, see Z. Zhang and M. G. Lagally, *Science* **276**, 377 (1997).
2. Y.-W. Mo and M. G. Lagally, *Surf. Sci.* **248**, 313 (1991); Y. W. Mo, J. Kleiner, M. P. Webb, M. G.





Cytotoxic T-cells

Infected cell


T-helper cells




HAART



HIV-Specific CD4+ T cell Responses following treatment in acute infection



Immune control:
Early treatment of acute HIV infection
followed by treatment interruption



.....

Immune control of HIV-1 after early treatment of acute infection

**Eric S. Rosenberg, Marcus Altfeld, Samuel H. Poon, Mary N. Phillips,
Barbara M. Wilkes, Robert L. Eldridge, Gregory K. Robbins,
Richard T. D'Aquila, Philip J. R. Goulder & Bruce D. Walker**

*Partners AIDS Research Center and Infectious Disease Division,
Massachusetts General Hospital and Harvard Medical School, Boston,
Massachusetts 02114, USA*

.....

Nature 2000

.....

Immune control of HIV-1 after early treatment of acute infection

Eric S. Rosenberg, Marcus Altfeld, Samuel H. Poon, Mary N. Phillips, Barbara M. Wilkes, Robert L. Eldridge, Gregory K. Robbins, Richard T. D'Aquila, Philip J. R. Goulder & Bruce D. Walker

*Partners AIDS Research Center and Infectious Disease Division,
Massachusetts General Hospital and Harvard Medical School, Boston,
Massachusetts 02114, USA*

.....

Nature 2000

Limited Durability of Viral Control following Treated Acute HIV Infection

Daniel E. Kaufmann^{1†}, Mathias Lichterfeld^{1†}, Marcus Altfeld¹, Marylyn M. Addo¹, Mary N. Johnston¹, Paul K. Lee¹, Bradford S. Wagner¹, Elizabeth T. Kalife¹, Daryl Strick¹, Eric S. Rosenberg¹, Bruce D. Walker^{1,2*}

1 Partners AIDS Research Center, Infectious Disease Unit, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts, United States of America, 2 Howard Hughes Medical Institute, Massachusetts General Hospital and Division of AIDS, Harvard Medical School, Boston, Massachusetts, United States of America

PLoS Medicine 2004

Chapter 3.

Insights from a raging epidemic



University of
KwaZulu-Natal









Kaye
Ajao

Krista
Dong


Doris Duke Medical Research Institute
Nelson R Mandela School of Medicine
KwaZulu Natal Province, South Africa




Emerging evidence from Africa of the importance of HIV-specific CTL

- Transmission of CTL escape variants to neonates
 - Goulder et al, *Nature* 2001
- Impact of HLA-B alleles on immune control
 - Kiepiela et al, *Nature* 2004
- PD-1 expression and HIV-specific T cell exhaustion
 - Day et al, *Nature* 2006
- Importance of Gag-specific T cell responses and control
 - Kiepiela et al, *Nature Medicine* 2007

The breadth of the Gag-specific CD8 response is associated with lower viral load




The breadth of the Env-specific CD8 response is associated with higher viral load



Chapter 4.

A late night conversation



The International HIV Controllers Study

The International HIV Controllers Study

Search the Site

SEARCH

INTERACTIVE INTERNATIONAL MEMBER MAP

- About HIV Controllers
- About the Study
- Study Members
- Enrolling in the Study
- For Health Professionals
- Funding Source
- News Center
- Contact

Are you HIV positive with a low viral load, without medications? You could help us better understand HIV. Consider enrolling in our study.


The goal of the International HIV Controllers Study is to help scientists understand why some people are able to control HIV infection without the need to take any medications. These findings could assist in the development of vaccines and new therapies.

© 2008 The International HIV Controllers Study
Partners AIDS Research Center • 149 13th Street, Room 5224 • Charlestown, MA 02129
617-726-5536 / 617-643-3643 • elltecontrollerstudy@partners.org
[Admin Login](#)

www.hivcontrollers.org


Genome-Wide Association Study: HIV control is associated with chromosome 6 polymorphisms

974 controllers and 2648 progressors



The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation

The International HIV Controllers Study*†




Chapter 5.

Science and Social Good

Female HIV Prevalence by Age: KwaZulu Natal

Annual Incidence: 9.1%



Abdool Karim Q, et al. Science 2010;
Kharsany AB, et al. JAIDS 2015; 70(3): 289–95

FRESH Study (2012-Present):


Females Rising through Education, Support and Health



Goals: 1. HIV prevention and poverty reduction
2. Immunology of hyperacute infection

<http://www.ragoninstitute.org/international/fresh/>

Learning from patients: Hyperacute HIV Infection



FRESH




Video linked in this article:

<https://www.massgeneral.org/News/pressrelease.aspx?id=2290>

FRESH Study

- Subjects:
 - Uninfected 18-23 year old women at high risk of HIV infection in an impoverished township
- Methods:
 - Provide a twice weekly empowerment, life skills, job readiness and HIV prevention education with the goal of employment after one year
 - Test twice weekly for HIV RNA by finger prick

A photograph of a modern, multi-story building. The building features a prominent glass facade on the right side and a central section with a grid of windows and a dark, textured facade. The base of the building is decorated with a series of circular murals. To the right of the building, there is a large tree and a brick building. The sky is overcast.

K-RITH: KwaZulu Natal Research Institute for TB and HIV


DDMRI



Zaza Ndhlovu


Thumbi Ndung'u

Kinetics of Hyperacute HIV Infection




Ndhlovu et al, *Immunity* 2015
Dong et al, *Lancet HIV* 2017

Massive HIV-specific T cell activation in acute HIV infection




Hyperacute HIV Infection

No Treatment



Atripla




Ndhlovu et al, *Immunity* 2015


Dong et al, *Lancet HIV* 2017

Ndung'u et al, *Science Immunology* 2018


Early treatment leads to enhanced HIV-specific CD8⁺ T cell function



Robust CD4⁺ T cell responses in treated acute HIV infection




HIV Gagp24 staining of a LN tissue from an early treated subject




Nuclei

Gag p24



Nuclei
Gagp2
BCL-6




Chapter 6.


Stock Markets and Social Networks




“A successful vaccine must **do better**
than natural immunity to HIV”



“A successful vaccine must do **as well as the best** natural immunity to HIV”




Measures of conservation: Sequence analysis




- Based on available sequence data
- Measures mutability of single amino acids
- Does not incorporate amino acid interactions or protein structure
- Does not correlate with fitness

Can we identify a subset of conserved residues that incur a maximal viral fitness cost?




Can we identify a subset of conserved residues that incur a maximal viral fitness cost?



Measures of conservation:

Fitness Landscapes



- Based on available sequence data
- Employs analysis tools used in the stock market
- Measures interdependence of amino acid mutations
- Suggests structural features are linked to fitness (Gag Capsid)

Dahriel et al, *PNAS* 2011

Ferguson et al, *Immunity* 2013

What can we learn from protein
structure?


Structure-based Network Analysis
(Think social networks)




Gaurav Gaiha, MD, PhD

Elizabeth Rossin, MD, PhD

Amino acid properties affect protein folding




Glycine
G




Tryptophan
W

Amino acid side chains influence structure



Proteins act as networks

Provides **LOCAL** and **GLOBAL** insight by transforming the system to **NODES** and **EDGES**



NODE = Amino Acid
EDGE = Intermolecular Interaction

Structure-based Network Analysis

Structural Representation




**INPUT: 3-dimensional atomic
level data from PDB file**

Concepts from Network Theory

– Degree Centrality


A measure of **LOCAL** Importance – # of Connections



Greater size = greater magnitude

Concepts from Network Theory– Betweenness Centrality

A measure of **GLOBAL** Importance – Involvement in Bridges



Greater size = greater magnitude

Consortia for HIV/AIDS Vaccine Development (CHAVD) RFA-AI-18-001

The purpose of this Funding Opportunity Announcement (FOA) is to solicit grant applications that propose to establish Consortia for HIV/AIDS Vaccine Development (CHAVD) to support a coordinated, multidisciplinary team(s) of researchers focused on iterative approaches to accelerate HIV vaccine development by addressing key immunogen design roadblocks to the discovery and development of a safe and effective antibody-mediated preventive HIV vaccine.

The following activities will NOT be supported by this FOA:

- Vaccine protection where the major mechanism of protection is not antibody-mediated

T cell-directed therapy in Melanoma

Screening



Week 12: swelling & progression



Week 14: improved



Week 16: continued improvement



Week 72: complete remission



Week 108: complete remission



Conclusions

- Durable natural immune control and possibly cure of HIV is achievable
- Durable immune control is mediated by CTL targeting of highly networked epitopes, providing a rational approach for HIV immunogen design
- Immediate treatment of hyperacute infection leads to induction of HIV-specific CD4 and CD8 T cells with enhanced function, and provides an ideal model for iterative immunotherapeutic intervention studies



Walker Lab

David Collins
Gaurav Gaiha
Jonathan Urbach
Geetha Mylvaganam
Xialong Li
Adrienne Yanez
Kiera Clayton
Krista Dong
Alicja Trocha
Natasha Ly
Paulo Dipinto

Thor Sandsted
Gaby Berger
Nicola McCafferty
Coco Difrancesco

Diane Rubin
Marina Boyarino
Jen Eng
Lexi Bazzini
Alex Cusson

Oxford

Philip Goulder

Ragon Institute

Todd Allen
Musie Gehbremichael
Alex Shalek
Sam Kazer

UKZN

Thumbi Ndung'u
Mope Radebe
Kamini Gounder
Funsho Ongushola
Nasreen Ismail
Karen Pretorius
Thandeka Nkosi

Broad Institute

Elizabeth Rossin
Mark Daley

MIT/Ragon

Arup Chakraborty
Vincent Dahirel
Andrew Ferguson
Darrell Irvine

FRESH Team

Thandi Sikhakhane
Bibi Makhanya
Landiwe Zimu
Hlengiwe Dladla
Hlengiwe Nzimande
Senelisiwe Gcaba
Nomfuselelo Ngcobo
Rethabile Maqalika
Sjabulile Ngcobo
Zandile Dlamini
Zandile Jali
Nompumelelo Mbatha
Nomfunmdo Luthuli
Nontobeko Zikalala
Zama Gumede
Ntombifuthi Ngcobo
Smangele Zungu
Amber Moodley
Mary Dong

NCI

Xiaojiang Gao
Mary Carrington



Howard Hughes
Medical Institute

BILL & MELINDA
GATES foundation

